TNF-alpha Levels in Tears: a Novel Biomarker to Assess the Degree of Diabetic Retinopathy

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2013 Nov 22

PMID 24259948

Citations 42

Authors

C Costagliola

V Romano

M De Tollis

F Aceto

R dellOmo

M R Romano

C Pedicino

F Semeraro

Affiliations

Soon will be listed here.

Abstract

We assess the level of tumour necrosis factor alpha (TNF-alpha) in tear fluids and other serum parameters associated with diabetes in different degrees of diabetic retinopathy. We have performed a prospective, nonrandomized, observational study. Study population consisted of 16 healthy subjects (controls) and 32 type 2 diabetic patients: 16 affected by proliferative diabetic retinopathy (PDR) and 16 with nonproliferative retinopathy (NDPR, background/preproliferative). Body mass index, urinary albumin, blood glucose, HbA1c, and tear levels of TNF-alpha were measured in all subjects. The value of glycaemia, microalbuminurea, and Body mass index in diabetic retinopathy groups were higher than those in control group (P < 0.05). Glycemia in NPDR: 6.6 mmol/L (range: 5.8-6.3); in PDR: 6.7 mmol/L (range: 6.1-7.2); in control: 5.7 mmol/L (range: 4.9-6.1); microalbuminurea in NPDR: 10.6 mg/L (range: 5.6-20); in PDR: 25.2 mg/L (range: 17-40); in control: 5.3 mg/L (range: 2.6-10); Body mass index in NPDR: 26 Kg/m(2) (range: 20.3-40); in PDR: 28 Kg/m(2) (range 20.3-52); in control: 21 Kg/m(2) (range 19-26). The TNF-alpha concentrations in tears increase with the severity of pathology and were lower in control group than in diabetic subjects. In the end, the level of TNF-alpha is highly correlated with severity of diabetic retinopathy and with nephropathy. Tear fluid collection may be a useful noninvasive method for the detection of proliferative diabetic retinopathy.

Citing Articles

Tear-fluid-derived biomarkers of ocular complications in diabetes: a systematic review and meta-analysis.

Polkamp M, Pham N, Wong W, Hardikar H, Kunte P, Cameron M BMC Med. 2025; 23(1):84.

PMID: 39939938 PMC: 11823092. DOI: 10.1186/s12916-025-03855-z.

A bibliometric and visualization analysis of electrochemical biosensors for early diagnosis of eye diseases.

Zhang F, Xu W, Deng Z, Huang J Front Med (Lausanne). 2025; 11:1487981.

PMID: 39867928 PMC: 11757256. DOI: 10.3389/fmed.2024.1487981.

Comprehensive analysis of systemic, metabolic, and molecular changes following prospective change to low-carbohydrate diet in adults with type 2 diabetes mellitus in India.

Bhandarkar N, Shetty K, Shetty N, Shetty K, Kiran A, Pindipapanahalli N Front Nutr. 2024; 11:1394298.

PMID: 39279894 PMC: 11397303. DOI: 10.3389/fnut.2024.1394298.

Neuroprotective Effects of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors (Gliflozins) on Diabetes-Induced Neurodegeneration and Neurotoxicity: A Graphical Review.

Gholami M, Coleman-Fuller N, Salehirad M, Darbeheshti S, Motaghinejad M Int J Prev Med. 2024; 15:28.

PMID: 39239308 PMC: 11376549. DOI: 10.4103/ijpvm.ijpvm_5_23.

Elevated aqueous TNF-α levels are associated with more severe functional and anatomic findings in eyes with diabetic macular oedema.

Chew S, Tran T, Sanfilippo P, Lim L, Sandhu S, Wickremasinghe S Clin Exp Ophthalmol. 2024; 52(9):981-990.

PMID: 39072984 PMC: 11620847. DOI: 10.1111/ceo.14425.

References

Meleth A, Agron E, Chan C, Reed G, Arora K, Byrnes G . Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005; 46(11):4295-301. DOI: 10.1167/iovs.04-1057. View

Limb G, CHIGNELL A, Green W, Leroy F, Dumonde D . Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol. 1996; 80(2):168-73. PMC: 505411. DOI: 10.1136/bjo.80.2.168. View

. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98(5 Suppl):807-22. View

Zhang X, Saaddine J, Chou C, Cotch M, Cheng Y, Geiss L . Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010; 304(6):649-56. PMC: 2945293. DOI: 10.1001/jama.2010.1111. View

Klein B, Knudtson M, Tsai M, Klein R . The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol. 2009; 127(9):1175-82. PMC: 2746055. DOI: 10.1001/archophthalmol.2009.172. View

Lechleitner M, Koch T, Herold M, Dzien A, Hoppichler F . Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Intern Med. 2000; 248(1):67-76. DOI: 10.1046/j.1365-2796.2000.00705.x. View

Zhang S, Wang J, Gao G, Shao C, Mott R, Ma J . Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J. 2005; 20(2):323-5. DOI: 10.1096/fj.05-4313fje. View

Muni R, Kohly R, Lee E, Manson J, Semba R, Schaumberg D . Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. JAMA Ophthalmol. 2013; 131(4):514-21. PMC: 3625475. DOI: 10.1001/jamaophthalmol.2013.2299. View

Liu J, Shi B, He S, Yao X, Willcox M, Zhao Z . Changes to tear cytokines of type 2 diabetic patients with or without retinopathy. Mol Vis. 2011; 16:2931-8. PMC: 3013072. View

10.

Costa G, Vindeirinho J, Cavadas C, Ambrosio A, Santos P . Contribution of TNF receptor 1 to retinal neural cell death induced by elevated glucose. Mol Cell Neurosci. 2012; 50(1):113-23. DOI: 10.1016/j.mcn.2012.04.003. View

11.

Moller D . Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2000; 11(6):212-7. DOI: 10.1016/s1043-2760(00)00272-1. View

12.

Ealovega M, Tabaei B, Brandle M, Burke R, Herman W . Opportunistic screening for diabetes in routine clinical practice. Diabetes Care. 2003; 27(1):9-12. DOI: 10.2337/diacare.27.1.9. View

13.

Franks W, Limb G, Stanford M, Ogilvie J, Wolstencroft R, CHIGNELL A . Cytokines in human intraocular inflammation. Curr Eye Res. 1992; 11 Suppl:187-91. DOI: 10.3109/02713689208999531. View

14.

Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A . [TNF-alpha level in the vitreous body. Increase in neovascular eye diseases and proliferative diabetic retinopathy]. Med Klin (Munich). 1995; 90(3):134-7. View

15.

. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98(5 Suppl):786-806. View

16.

Hotamisligil G . Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-7. DOI: 10.1038/nature05485. View

17.

Henricsson M, Tyrberg M, Heijl A, Janzon L . Incidence of blindness and visual impairment in diabetic patients participating in an ophthalmological control and screening programme. Acta Ophthalmol Scand. 1996; 74(6):533-8. DOI: 10.1111/j.1600-0420.1996.tb00729.x. View

18.

. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011; 35 Suppl 1:S64-71. PMC: 3632174. DOI: 10.2337/dc12-s064. View

19.

Joussen A, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S . Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002; 16(3):438-40. DOI: 10.1096/fj.01-0707fje. View

20.

Goldberg R . Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009; 94(9):3171-82. DOI: 10.1210/jc.2008-2534. View